HCPCS Level II code Q5141 identifies a 1 mg unit of adalimumab-aaty, a biosimilar therapeutic biologic administered by injection. This code matters nationally because biosimilar versions of high-cost biologics influence payer coverage policies, utilization management, and overall drug spending across outpatient and infusion settings. Providers and payers use unit-level HCPCS codes like Q5141 to report administered doses, support billing for drug acquisition and administration, and enable tracking of biosimilar uptake.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise overview of the code’s clinical role and typical sites of service, along with the types of benchmarks and policy areas commonly associated with biosimilar injectable agents—coverage criteria, unit-based billing practices, and implications for outpatient administration workflows. The summary highlights where data was not provided in the input and flags that detailed payer-specific coverage rules, reimbursement rates, and associated diagnosis coding are not included here. The content is intended for a national audience of payers, provider billing teams, and policy analysts seeking a clear reference for HCPCS Level II code Q5141 and its role in biosimilar biologic billing.